Halozyme Reports Fourth Quarter And Full Year 2023 Financial Results
Bristol Myers reveals subcutaneous Opdivo data in kidney cancer as I-O battle heads to new front
Halozyme Announces Takeda Received European Commission Approval for HYQVIA
Roche’s Tecentriq SC receives EC approval for cancer treatment
Halozyme Announces Takeda Receives FDA Approval for HYQVIA® Co-formulated with ENHANZE® as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)